Pre-Clinical Research
Filter News
Found 7,464 articles
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 24, 2020.
-
Twist Bioscience Announces Positive Preclinical Data for SARS-CoV-2 Antibodies
11/23/2020
Twist Bioscience Corporation (Nasdaq: TWST) today announced preclinical data for three of its proprietary antibodies against the S1 protein in SARS-CoV-2, the virus that causes COVID-19.
-
IPA Selects Polytope Formulations for Pre-Clinical Studies
11/23/2020
IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that it has selected more than ten, unique monoclonal antibodies for further preclinical development
-
Arizona BioTech Company Successfully Completes Pre-Clinical Testing for Vaccine Alternative to Prevent COVID-19 Infection, Ready for Human Trials
11/23/2020
Newly published study shows KEPTIDE™ COVID, a self-administered nasal spray, protects the lungs and kidneys and prevents death from COVID-19 infection in humanized mice.
-
ImmunityBio Announces Publication of Preclinical Data Demonstrating IL-15 Superagonist N-803 Improves Natural Killer-Mediated Tumor Cell Killing
11/23/2020
N-803 Boosts CD34+ Progenitor-Derived NK Cell Expansion and Functionality Adding N-803 to NK Cell Therapy has Potential to Improve Cancer Immunotherapy
-
Mymetics to Advance Preclinical Studies for Virosome-based COVID-19 Vaccine through Innosuisse Grant
11/18/2020
Mymetics SA, a subsidiary of Mymetics Corporation, a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases, and Insel Gruppe AG, of which the Inselspital, Bern University Hospital, are part of, announced that they have been awarded a grant from the Swiss Innovation Agency.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 17, 2020.
-
VECT-HORUS and CERIMED Announce Collaboration to Support the Development of VECT-HORUS’ Theragnostic Agents
11/17/2020
VECT-HORUS, a biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, has announced the signing of a collaboration agreement with CERIMED (European Centre for Research in Medical Imaging) to support the preclinical development of VECT-HORUS’ theragnostic agents.
-
BiomX Presents Preclinical Results of Phage Targeting Klebsiella pneumoniae for Primary Sclerosing Cholangitis and Inflammatory Bowel Disease
11/16/2020
Presentation featured at The Liver Meeting® 2020, the AASLD Annual Meeting, details support for the design of phage therapy candidate BX003
-
Cytokinetics Announces Preclinical Data for CK-3773274 and CK-3772271 Presented at the AHA Scientific Sessions 2020
11/16/2020
New Findings from Studies of Cardiac Myosin Inhibitors in Animal Models of Hypertrophic Cardiomyopathy and Heart Failure with Preserved Ejection Fraction
-
9 Meters Biopharma Announces Positive Preclinical Data for NM-102, a Gut Microbiome Modulator in an Immune Checkpoint Inhibitor Failure Model
11/16/2020
NM-102, a novel next-generation microbiome modulator, shows positive effect in an aggressive immune checkpoint inhibitor failure melanoma model
-
CalciMedica Announces Publication of Preclinical Data Demonstrating the Pathological Role of Microglial CRAC Channels in Ischemic Stroke
11/13/2020
CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of severe acute and chronic inflammatory diseases, today announced the publication of preclinical data demonstrating a pathological role for CRAC channel-mediated microglial calcium activity in ischemic brain injury in the peer-reviewed journal Stroke.
-
Silverback Therapeutics Presents Preclinical Data for SBT8230 at AASLD The Liver Meeting Digital Experience
11/13/2020
Silverback Therapeutics, Inc. (“Silverback”) (“the Company”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue-targeted therapeutics, will present preclinical data for SBT8230 at AASLD The Liver Meeting Digital Experience (November 13-16, 2020).
-
twoXAR Pharmaceuticals Presents Preclinical Data Demonstrating Positive Safety and Tolerability of Two Novel NASH Treatment Candidates
11/13/2020
twoXAR Pharmaceuticals, a drug discovery and development company focused on bringing first-in-class small molecules to market, today announced that two novel leads for the potential treatment of non-alcoholic steatohepatitis (NASH), TXR-611 and TXR-612, demonstrated significant efficacy and excellent tolerability in preclinical studies.
-
Vaxart Reports Third Quarter 2020 Financial Results and Provides Business Update
11/12/2020
Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced financial results for the third quarter of 2020 and provided a corporate update, including updates on its oral COVID-19 vaccine pre-clinical studies and clinical trials.
-
Harpoon Therapeutics Presents Encouraging Preclinical Data for HPN601 EpCAM ProTriTAC™ Program at 35th SITC Annual Meeting
11/12/2020
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today presented preclinical data on HPN601 for the treatment of solid tumors at the 35 th Society for Immunotherapy of Cancer (SITC) virtual annual meeting. HPN601 is the first conditionally active T cell engager program from Harpoon. It targets the tumor antigen epithelial cell adhesion molecule (EpCAM) and is based
-
Kineta Presents New Preclinical Data at the 2020 SITC Annual Meeting on its VISTA Antagonist Antibodies
11/12/2020
Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology and neuroscience, announced today the presentation of new preclinical data on its VI
-
Xilio Therapeutics Presents Promising Preclinical Tumor-Selective Efficacy and Safety Data for XTX201 (IL-2) and XTX101 (anti-CTLA-4) at SITC
11/12/2020
Xilio Therapeutics, a biotechnology company developing potent, tumor-selective immunotherapies for patients with cancer, today announced the presentation of preclinical data of its lead investigational therapies: XTX201, a tumor-selective IL-2, and XTX101, a tumor-selective anti-CTLA-4 antibody
-
NANOBIOTIX Announces Positive New Pre-clinical Data Suggesting Radioenhancer NBTXR3 Could Have a Significant Impact in Immunotherapy
11/12/2020
NANOBOTIX, a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, announced positive new in vivo pre-clinical data from two studies at The Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting.
-
EXUMA Biotech Presents Preclinical Data on Rapid Point-of-Care "rPOC"Subcutaneous
11/11/2020
EXUMA Biotech Corp., a clinical-stage biotechnology company discovering and developing CAR-T products and delivery solutions for liquid and solid tumors, today announced that preclinical data for the company's next-generation rapid point-of-care, or "rPOC", subcutaneous (SC) autologous CAR-T platform,